PHENYLBUTAZONE PHARMACOKINETICS AND BIOAVAILABILITY IN THE DROMEDARY CAMEL (CAMELUS DROMEDARIUS)

Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two‐period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two‐compartment open model, with a low volume of distribution (0....

Full description

Saved in:
Bibliographic Details
Published in:Journal of veterinary pharmacology and therapeutics 1997-02, Vol.20 (1), p.54-60
Main Authors: Kadir, A., Ali, B.H., Al Hadrami, G., Bashir, A.K., Landoni, M.F., Lees, P.
Format: Article
Language:English
Subjects:
Animals
Anti-Inflammatory Agents, Non-Steroidal - administration & dosage
Anti-Inflammatory Agents, Non-Steroidal - blood
Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics
Biological Availability
Blood Specimen Collection - veterinary
Camelus - metabolism
Chromatography, High Pressure Liquid - veterinary
Cross-Over Studies
Dose-Response Relationship, Drug
Female
Half-Life
Injections, Intramuscular - veterinary
Injections, Intravenous - veterinary
Oxyphenbutazone - blood
Phenylbutazone - administration & dosage
Phenylbutazone - blood
Phenylbutazone - pharmacokinetics
Thromboxane B2 - blood
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Phenylbutazone was administered intravenously and intramuscularly at a dosage rate of 4.4 mg/kg to a group of 6 female camels in a two‐period crossover study. After intravenous (i.v.) administration, disposition was characterised by a two‐compartment open model, with a low volume of distribution (0.174 l.kg–1), and distribution and elimination half‐lives of 0.43 and 12.51 h, respectively. After intramuscular (i.m.) dosing absorption was relatively rapid with absorption half‐time and time of maximal concentration values of 1.14 and 3.95 h, respectively. Plateau concentrations of phenylbutazone in plasma were obtained between 2 and 12 h and mean bioavailability was 97%, although this was subject to wide inter‐animal differences. Plasma concentrations of the phenylbutazone metabolite, oxyphenbutazone, were low after iv dosing and generally undetectable after im administration, indicating that it is unlikely to contribute significantly to the pharmacological effects produced by phenylbutazone administration. An indication was obtained that phenylbutazone inhibited the ex vivo synthesis of serum thromboxane B2 (TxB2) for 24 h after i.v. dosing, but this finding requires confirmation.
ISSN:0140-7783
1365-2885
DOI:10.1046/j.1365-2885.1997.04427.x